Deep Learning and Pathomics Analyses Reveal Cell Nuclei as Important Features for Mutation Prediction of BRAF-Mutated Melanomas.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
06 2022
Historique:
received: 10 12 2020
revised: 29 07 2021
accepted: 26 09 2021
pubmed: 11 11 2021
medline: 25 5 2022
entrez: 10 11 2021
Statut: ppublish

Résumé

Image-based analysis as a method for mutation detection can be advantageous in settings when tumor tissue is limited or unavailable for direct testing. In this study, we utilize two distinct and complementary machine-learning methods of analyzing whole-slide images for predicting mutated BRAF. In the first method, whole-slide images of melanomas from 256 patients were used to train a deep convolutional neural network to develop a fully automated model that first selects for tumor-rich areas (area under the curve = 0.96) and then predicts for mutated BRAF (area under the curve = 0.71). Saliency mapping was performed and revealed that pixels corresponding to nuclei were the most relevant to network learning. In the second method, whole-slide images were analyzed using a pathomics pipeline that first annotates nuclei and then quantifies nuclear features, showing that mutated BRAF nuclei were significantly larger and rounder than BRAF‒wild-type nuclei. Finally, we developed a model that combines clinical information, deep learning, and pathomics that improves the predictive performance for mutated BRAF to an area under the curve of 0.89. Not only does this provide additional insights on how BRAF mutations affect tumor structural characteristics, but machine learning‒based analysis of whole-slide images also has the potential to be integrated into higher-order models for understanding tumor biology.

Identifiants

pubmed: 34757067
pii: S0022-202X(21)02405-2
doi: 10.1016/j.jid.2021.09.034
pmc: PMC9054943
mid: NIHMS1752876
pii:
doi:

Substances chimiques

BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1650-1658.e6

Subventions

Organisme : NIH HHS
ID : S10 OD018338
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA225450
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA210972
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NIH HHS
ID : S10 OD010582
Pays : United States

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Nat Commun. 2016 Aug 16;7:12474
pubmed: 27527408
J Transl Med. 2012 Jul 09;10:85
pubmed: 22554099
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2970-E2979
pubmed: 29531073
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Sci Rep. 2020 Apr 20;10(1):6623
pubmed: 32313236
Am J Transl Res. 2009;1(1):35-43
pubmed: 19966936
Nat Cancer. 2020 Aug;1(8):800-810
pubmed: 35122049
Clin Cancer Res. 2012 Jun 15;18(12):3242-9
pubmed: 22535154
Genome Biol. 2006;7(10):R100
pubmed: 17076895
Front Bioeng Biotechnol. 2019 Apr 02;7:53
pubmed: 31001524
Nat Med. 2018 Oct;24(10):1559-1567
pubmed: 30224757
Methods Mol Biol. 2016;1418:111-41
pubmed: 27008012
Diagnostics (Basel). 2020 May 30;10(6):
pubmed: 32486314
Nat Cancer. 2020 Aug;1(8):789-799
pubmed: 33763651
JAMA Oncol. 2015 Jun;1(3):359-68
pubmed: 26146664
PLoS Med. 2008 Jun 3;5(6):e120
pubmed: 18532874
Nat Med. 2021 May;27(5):775-784
pubmed: 33990804
Nat Med. 2019 Aug;25(8):1301-1309
pubmed: 31308507
Clin Cancer Res. 2021 Jan 1;27(1):131-140
pubmed: 33208341
Pigment Cell Melanoma Res. 2011 Apr;24(2):345-51
pubmed: 21324100
Med Image Anal. 2019 Dec;58:101563
pubmed: 31561183
AJNR Am J Neuroradiol. 2020 Apr;41(4):700-705
pubmed: 32273326
Pigment Cell Melanoma Res. 2010 Dec;23(6):763-70
pubmed: 20874733
J Invest Dermatol. 2007 Apr;127(4):900-5
pubmed: 17159915

Auteurs

Randie H Kim (RH)

Ronald O. Perelman Department of Dermatology, Grossman School of Medicine, New York University, New York, New York, USA; Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA.

Sofia Nomikou (S)

Department of Pathology, Grossman School of Medicine, New York University, New York, New York, USA; Institute for Systems Genetics, Grossman School of Medicine, New York University, New York, New York, USA.

Nicolas Coudray (N)

Applied Bioinformatics Laboratories, Grossman School of Medicine, New York University, New York, New York, USA; Department of Cell Biology, Skirball Institute of Biomolecular Medicine, Grossman School of Medicine, New York University, New York, New York, USA.

George Jour (G)

Ronald O. Perelman Department of Dermatology, Grossman School of Medicine, New York University, New York, New York, USA; Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA; Department of Pathology, Grossman School of Medicine, New York University, New York, New York, USA.

Zarmeena Dawood (Z)

Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA.

Runyu Hong (R)

Institute for Systems Genetics, Grossman School of Medicine, New York University, New York, New York, USA.

Eduardo Esteva (E)

Department of Biomedical Engineering, Tandon School of Engineering, New York University, New York, New York, USA.

Theodore Sakellaropoulos (T)

Department of Pathology, Grossman School of Medicine, New York University, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, Grossman School of Medicine, New York University, New York, New York, USA.

Douglas Donnelly (D)

Laura and Isaac Perlmutter Cancer Center, Grossman School of Medicine, New York University, New York, New York, USA.

Una Moran (U)

Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA.

Aristides Hatzimemos (A)

Ronald O. Perelman Department of Dermatology, Grossman School of Medicine, New York University, New York, New York, USA.

Jeffrey S Weber (JS)

Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, Grossman School of Medicine, New York University, New York, New York, USA.

Narges Razavian (N)

Deparmtent of Radiology, Grossman School of Medicine, New York University, New York, New York, USA; Department of Population Health, Grossman School of Medicine, New York University, New York, New York, USA.

Iannis Aifantis (I)

Department of Pathology, Grossman School of Medicine, New York University, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, Grossman School of Medicine, New York University, New York, New York, USA.

David Fenyo (D)

Institute for Systems Genetics, Grossman School of Medicine, New York University, New York, New York, USA; Department of Biochemistry and Molecular Pharmacology, Grossman School of Medicine, New York University, New York, New York, USA.

Matija Snuderl (M)

Department of Pathology, Grossman School of Medicine, New York University, New York, New York, USA.

Richard Shapiro (R)

Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA; Department of Surgery, Grossman School of Medicine, New York University, New York, New York, USA.

Russell S Berman (RS)

Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA; Department of Surgery, Grossman School of Medicine, New York University, New York, New York, USA.

Iman Osman (I)

Ronald O. Perelman Department of Dermatology, Grossman School of Medicine, New York University, New York, New York, USA; Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA.

Aristotelis Tsirigos (A)

Department of Pathology, Grossman School of Medicine, New York University, New York, New York, USA; Applied Bioinformatics Laboratories, Grossman School of Medicine, New York University, New York, New York, USA. Electronic address: Aristotelis.Tsirigos@nyulangone.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH